UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000060325
Receipt number R000069005
Scientific Title Clinical results of romosozumab in the treatment of osteoporosis
Date of disclosure of the study information 2026/01/12
Last modified on 2026/01/11 14:31:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical results of romosozumab in the treatment of osteoporosis

Acronym

Clinical results of romosozumab in the treatment of osteoporosis

Scientific Title

Clinical results of romosozumab in the treatment of osteoporosis

Scientific Title:Acronym

Clinical results of romosozumab in the treatment of osteoporosis

Region

Japan


Condition

Condition

Osteoporosis

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the treatment outcomes of romosozumab in real-world clinical practice.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Changes in lumbar and proximal femur bone mineral density, changes in bone metabolism markers, incidence of fractures, and incidence of side effects

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Severe osteoporosis

Key exclusion criteria

1) a history of myocardial infarction or stroke
2) a history of hypersensitivity to romosozumab or its components
3) pregnancy, suspected pregnancy, or breastfeeding
4) failure to obtain written informed consent for participation in the study

Target sample size

500


Research contact person

Name of lead principal investigator

1st name RUI
Middle name
Last name NIIMI

Organization

Niimi orthopaedics surgery clinic

Division name

Orthopaedic surgery

Zip code

5110079

Address

2029, Ako Kuwanas city Mie prefecture

TEL

0594332133

Email

furikakefuri@hotmail.co.jp


Public contact

Name of contact person

1st name RUI
Middle name
Last name NIIMI

Organization

Niimi orthopaedics surgery clinic

Division name

Orthopaedic surgery

Zip code

5110079

Address

2029, Ako Kuwana city Mie prefecture

TEL

0594332133

Homepage URL

https://niimi-op.jp/

Email

furikakefuri@hotmail.co.jp


Sponsor or person

Institute

Niimi orthopaedics clinic

Institute

Department

Personal name

RUI NIIMI


Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Niimi orthopaedic surgery clinic

Address

2029, Ako Kuwana city Mie prefecture

Tel

0594332133

Email

furikakefuri@hotmail.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW

δΈ‰ι‡ηœŒ


Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 01 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 01 Month 01 Day

Date of IRB

2025 Year 12 Month 30 Day

Anticipated trial start date

2019 Year 03 Month 04 Day

Last follow-up date

2035 Year 12 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2026 Year 01 Month 11 Day

Last modified on

2026 Year 01 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069005